EQS-News: Marinomed Biotech AG reports preliminary financial figures for the first half of 2024
   EQS-News: Marinomed Biotech AG / Key word(s): Preliminary Results/Half
   Year Results
   Marinomed Biotech AG reports preliminary financial figures for the first
   half of 2024

   20.08.2024 / 18:00 CET/CEST
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Marinomed Biotech AG reports preliminary financial figures for the first
   half of 2024

     • Revenues of EUR 2.5 million generated in the first half of 2024 (H1
       2023: EUR 5.2 million); cash and cash equivalents as of 30.06.2024 at
       EUR 0.9 million (31.12.2023: EUR 2.6 million)
     • Court restructuring proceedings without self-administration opened on
       August 14, 2024; Marinomed shares now listed in the standard market
       continuous segment of the Vienna Stock Exchange
     • New partnerships for Carragelose and Solv4U and progress with new
       Carragelose products

   Korneuburg, Austria, 20. August 2024 – Marinomed Biotech AG (VSE:MARI)
   reports revenues of EUR 2.5 million for the first half of 2024. This
   corresponds to a decline of around 53% compared to the first half of 2023
   (EUR 5.2 million). As already reported, this is mainly due to high
   inventory levels at Marinomed's marketing partners and therefore fewer
   orders. Compared to the first quarter of 2024, however, significantly more
   Carragelose products were delivered and revenues more than doubled in Q2
   (from EUR 0.7 million to EUR 1.7 million). The operating result (EBIT)
   amounted to EUR -3.2 million (H1 2023: EUR -2.9 million). Cash and cash
   equivalents fell to EUR 0.9 million compared to end of 2023 (EUR 2.6
   million). After it was not possible to raise the funds needed to secure
   liquidity in the short term, court restructuring proceedings without
   self-administration were initiated on August 14, 2024, at the Company's
   request.

   Marinomed was able to push ahead with several initiatives in the first
   half of the year: An existing Carragelose partnership with a leading
   consumer healthcare player was expanded to include selected countries in
   Europe and beyond. In connection with this, Marinomed was able to record a
   first milestone in the amount of EUR 0.5 million. There is also news about
   the two new Carragelose products: The clinical trial in Spain, in which
   the effectiveness of Carragelose eye drops against dry eye symptoms was
   tested, is currently being evaluated and initial results are expected
   shortly. In addition, the anti-allergic nasal spray Coldamaris Allergie
   was launched in the first quarter of 2024. In the second quarter, this
   product already achieved the second-best result after Coldamaris plus,
   underlining the need for products to treat hay fever.

   In addition to Aché Laboratórios in Brazil, the Solv4U unit has now
   entered into its third long-term partnership with Unither Pharmaceuticals
   in France. Both companies are evaluating the potential of the Marinosolv
   technology to sustainably improve the availability of drugs.

   Andreas Grassauer, CEO of Marinomed, says: “Despite intensive efforts, we
   have unfortunately not succeeded in raising the funds required in the
   short term to secure the Company's liquidity. It was therefore necessary
   to apply for restructuring proceedings. Our top priority is now the
   sustainable stabilization of Marinomed in the course of the restructuring
   proceedings, which were opened on August 14, 2024. The second priority is
   to generate funds from revenues, partnerships and the implementation of
   strategic options for the Carragelose business. We are aiming to make a
   decision here by the end of the year. We are also in negotiations with
   investors to secure the Company's liquidity.”

   “The restructuring process offers us the opportunity to improve the
   Company's financial situation, while continuing our activities and
   preserving the Company's values. However, further cost-saving measures are
   necessary; this also affects our financial reporting. After the half-year
   financial report 2024, we will only publish financial reports on the basis
   of the Austrian Commercial Code (UGB). We will also refrain from
   publishing quarterly reports. As the publication of the full half-year
   financial report 2024 had to be postponed due to the current situation, we
   hereby provide an update on the key figures. The publication of the
   half-year financial report 2024 is planned after the three-month
   restructuring phase. We continue to strive for maximum transparency and
   are grateful for the support of our stakeholders,” Pascal Schmidt, CFO of
   Marinomed, added.

   Selected preliminary key financial figures for H1 2024
   Disclaimer: These selected preliminary key figures as of June 30, 2024,
   have been prepared on a going concern basis after successful completion of
   the restructuring process. The publication of the half-year financial
   report 2024 and the review report is planned after completion of the
   restructuring process.

                    All amounts in € thousand     H1 2024         H1 2023
                                     Revenues         2,463.9         5,228.5
                      Operating result (EBIT)        -3,225.3        -2,906.4
                                 R&D expenses        -3,137.1        -3,712.4
   Cash flow utilized by operating activities        -1,890.0        -2,275.4
                                                   30.06.2024      31.12.2023
                    Cash and cash equivalents           911.5         2,588.8
                          Balance sheet total        11,323.0        14,611.7

   On August 14, 2024, restructuring proceedings without self-administration
   were opened for Marinomed Biotech AG. The Company's shares are now
   tradable on the standard market continuous of the Vienna Stock Exchange.
   Dr. Ulla Reisch (deputy: Mag. Georg Hampel) was appointed as insolvency
   administrator. All information on the restructuring proceedings of
   Marinomed Biotech AG can be found here:
   (1)https://www.marinomed.com/en/investors-esg/restructuring-proceedings

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline and globally marketed therapeutics. The
   Company develops innovative patent-protected products in the therapeutic
   areas immunology and virology based on the platform Marinosolv® and the
   virus-blocking activity of Carragelose®. The Marinosolv® technology
   improves the solubility and bioavailability of hardly soluble compounds
   and is used to develop new therapeutics for autoreactive immune disorders.
   The virology segment includes Carragelose®-based over-the-counter (OTC)
   products to prevent and treat respiratory viral infections that are
   partnered in more than 40 countries. The Company is headquartered in
   Korneuburg, Austria, and is listed on the Vienna Stock Exchange
   (VSE:MARI). For further information, please visit:
   (2)https://www.marinomed.com.

   For further inquiries contact:

   Marinomed Biotech AG
   PR & IR: Lucia Ziegler
   T: +43 2262 90300 158
   E-Mail: (3)pr@marinomed.com
   E-Mail: (4)ir@marinomed.com

   Disclaimer

   This press release contains forward-looking statements, which are based on
   current views, expectations and projections of the management of Marinomed
   Biotech AG about future events. These forward-looking statements are
   subject to risks, uncertainties and assumptions that could cause actual
   results, performance or events to differ materially from those described
   in, or expressed or implied by, such statements. The current views,
   expectations and projections of the management of Marinomed Biotech AG may
   be identified by the context of such statements or words such as
   “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
   and “target”. Forward-looking statements are only valid as of the date
   they are made and Marinomed Biotech AG does not assume any obligation to
   update, review or revise any forward-looking statements contained in this
   press release whether as a result of new information, future developments
   or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
   trademarks of Marinomed Biotech AG. These trademarks may be owned or
   licensed in select locations only.

    

   ══════════════════════════════════════════════════════════════════════════

   20.08.2024 CET/CEST This Corporate News was distributed by EQS Group AG.
   www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 1971719


    
   End of News EQS News Service


   1971719  20.08.2024 CET/CEST

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=48baa726d0b243dceaf56eab7392d101&application_id=1971719&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1971719&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   3. mailto:pr@marinomed.com
   4. mailto:ir@marinomed.com

result hk

togel hari ini

result hk

pengeluaran hk

By adminn